BNP Paribas Upgrades Phibro Animal Health (NASDAQ:PAHC) to "Hold"

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was upgraded by research analysts at BNP Paribas to a "hold" rating in a research note issued to investors on Monday,Zacks.com reports.

Several other equities analysts also recently issued reports on PAHC. BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price on the stock in a research report on Monday. Morgan Stanley upped their target price on Phibro Animal Health from $20.00 to $21.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Finally, Wall Street Zen raised Phibro Animal Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, Phibro Animal Health presently has an average rating of "Hold" and a consensus price target of $20.80.

Phibro Animal Health Trading Down 1.1%

Shares of NASDAQ:PAHC opened at $24.45 on Monday. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $26.55. The company has a debt-to-equity ratio of 2.67, a current ratio of 2.91 and a quick ratio of 1.23. The firm has a market capitalization of $990.96 million, a P/E ratio of 31.35, a P/E/G ratio of 0.47 and a beta of 0.74. The business's 50-day moving average is $21.39 and its 200 day moving average is $21.89.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.11. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. The firm had revenue of $347.80 million for the quarter, compared to the consensus estimate of $352.41 million. On average, research analysts predict that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC grew its position in Phibro Animal Health by 0.5% during the first quarter. Acadian Asset Management LLC now owns 782,939 shares of the company's stock valued at $16,713,000 after buying an additional 4,144 shares during the period. Jane Street Group LLC grew its position in shares of Phibro Animal Health by 65.3% during the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company's stock valued at $724,000 after acquiring an additional 13,404 shares during the period. Millennium Management LLC grew its position in shares of Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company's stock valued at $7,733,000 after acquiring an additional 154,281 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock valued at $260,000 after acquiring an additional 546 shares during the period. Finally, Trexquant Investment LP acquired a new stake in shares of Phibro Animal Health during the 1st quarter valued at about $385,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.